- Beckman Coulter Life Sciences, Abcam, and SCIEX1, subsidiaries of Danaher, are supporting the Human Immunome Project (HIP), a global nonprofit, in its efforts to decode and model the immune system.
- Danaher’s participation will provide HIP access to research tools to generate advanced and standardized immunological data from diverse populations worldwide.
- The Human Immunome Project is building the world’s most comprehensive immunological dataset as well as best-in-class AI models of the immune system to identify new medical targets and accelerate development of diagnostics and therapeutics to improve health worldwide.
NEW YORK, December 3, 2024 — Three subsidiaries of Danaher Corporation (“Danaher”), a leading global life sciences and diagnostics innovator, are supporting the nonprofit Human Immunome Project (HIP) with access to reagents, assays, and equipment. Danaher’s participation will help HIP to generate the world’s most comprehensive immunological dataset and provide a transformative new resource to the scientific and medical communities.
The Human Immunome Project is a global, nonprofit, pre-competitive scientific initiative to decode and model the immune system to improve health for all. Together with its partners, HIP will collect biological samples at 150 study sites spread globally. The participation of Danaher subsidiaries will support HIP’s effort to develop Immune Monitoring Kits (IMKs)—a new tool that compiles multiple tests to assess the function of the immune system and produce standardized data.
“The participation of Danaher represents a huge step toward producing advanced and standardized immunological data at HIP study sites worldwide,” said HIP CEO Dr. Hans Keirstead. “These data and the models they will inform can empower the scientific and medical communities to develop personalized life-saving medical interventions and diagnostics to improve health for populations worldwide.”
The IMKs are key to HIP’s scaling strategy, combining multiple complex assays in one clinical lab. By combining the most relevant assays in one central kit, the IMKs are expected to expedite the ability to capture overall human immune function and sample diverse populations over time. HIP’s efforts are expected to also significantly strengthen scientific capacity in low- and middle-income countries.
“The immune system is incredibly complex and we’re at an exciting time when analytical tools and computational approaches can be applied at scale to resolve this complexity in new ways,” said Dr. Will Blake, Chief Technology Officer, DH Life Sciences LLC, a subsidiary of Danaher. “We’re proud that products and workflow solutions from across Danaher will help power HIP’s efforts to develop AI models to better understand the immune system’s critical and varied contributions to health and disease.”
The Human Immunome Project will begin data collection in 2025 with the establishment of its first global study sites. These data will to inform best-in-class AI models of the immune system, offering a revolutionary new tool to advance our understanding of the immune system, uncover new biomarkers and targets, and accelerate our ability to create new diagnostics and therapies for the world’s most pressing health challenges.
***
About the Human Immunome Project (HIP)
The Human Immunome Project (HIP) is a global nonprofit dedicated to comprehensively mapping and modeling the human immune system with the goal of accelerating medical research, advancing drug and diagnostic discovery, and, ultimately, improving health outcomes for populations globally. HIP is a US-registered 501(c)(3) organization.
Contact
Liza Kane-Hartnett, Liza@ImmunomeProject.org
1. “Beckman Coulter Life Sciences” is part of the legal entity known as Beckman Coulter, Inc. SCIEX is the legal entity known as AB Sciex Pte. Ltd.
Responses